enVVeno Medical (NVNO) Long-Term Deferred Tax (2020 - 2021)

enVVeno Medical's quarterly Long-Term Deferred Tax came in at $14.5 million in Q4 2021, up 35.24% year-on-year from $10.7 million in Q4 2020, and up 35.24% quarter-over-quarter from $10.7 million in Q4 2020.

enVVeno Medical has reported Long-Term Deferred Tax for 2 years, with the latest figure at $14.5 million in Q4 2021.

  • For the quarter ending Q4 2021, Long-Term Deferred Tax rose 35.24% year-over-year to $14.5 million; the trailing twelve-month figure through Dec 2021 stood at $14.5 million (up 35.24% YoY), and the FY2021 full-year result was $14.5 million, up 35.24% from the prior year.
  • Long-Term Deferred Tax for Q4 2021 stood at $14.5 million, up from $10.7 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $14.5 million in Q4 2021, with the low at $10.7 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 enVVeno Medical 6.99 Mn 6.99 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 14.48 Mn
Dec 31, 2020 10.71 Mn